NGS Streamlines Biomarker Testing in Solid Tumors
Chen, PharmD, MS, BCOP, CPP, discusses the role of next-generation sequencing in improving biomarker testing and treatment planning for solid tumors.
- Experts including Traina, MD, FASCO, and Demetria Smith-Graziani, MD, MPH, share insights on this topic.
- Other notable experts such as Mark Agulnik, MD, Mrinal M. Zuckerman, MD, and Naval G. Daver, MD, also contribute to the discussion.
Next-generation sequencing improves biomarker testing and treatment planning in solid tumors.
Additional experts, including Jessica Altman, MD, Amir T. Roboz, MD, and Joshua Zeidner, MD, provide further perspectives on the benefits of NGS in oncology.
Author's summary: NGS enhances biomarker testing for solid tumors.